Smith & Nephew and Johnson & Johnson Orthopaedics Merger Talks Collapse
Merger discussions between Smith & Nephew and the orthopaedics unit of Johnson & Johnson have reportedly ended due to a disagreement over leadership roles.
Stocks · News reference
Smith+Nephew Receives 510(k) Clearance From FDA And Completes First Surgical Cases With LANDMARK Total Knee System
Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and has completed the first surgical cases with
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Smith & Nephew Announces Sterling Dividend Amount
Smith & Nephew plc has confirmed the sterling equivalent for its previously announced interim dividend of 15.6 US cents per share.
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
Smith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant across 12 key markets, expanding its Sports Medicine portfolio. The product is backed by clinical evidence showing superior knee outcomes and pain relief over five years. The global cartilage repair market is projected to grow from $5.98 billion in 2024 to $8.04 billion by 2030 at a 5.1% CAGR.
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
Smith+Nephew announced the commercial launch of CARTIHEAL AGILI-C, an innovative cartilage repair implant, across Europe. The aragonite-based scaffold will be presented at the ICRS Summit in Portugal (October 8-10). A randomized controlled trial published in the American Journal of Sports Medicine demonstrated clinical superiority over standard surgical care, with patients showing improved pain relief and functional outcomes over 5 years. The implant will initially be available in 8 European countries with plans for further expansion.